Dr Amit Shah

Professional statement

Dr Amit Shah is a distinguished, board-certified consultant in haemato and medical oncology based in Leicester. His areas of expertise include non-small cell lung cancer, breast cancer, non-Hodgkin lymphoma, chronic lymphocytic leukaemia, myelodysplastic syndrome, myelofibrosis, acute myeloid leukaemia, sickle cell disease, and haemophilia. In addition, Dr Shah is also highly proficient in image-guided surgical procedures including endovascular repair, stenting, balloon dilation, and soft tissue and bone biopsies.

Currently, Dr Shah consults privately at NHS Leicester, Leicestershire and Rutland Integrated Care Board, at Leicester General Hospital, at Leicester Royal Infirmary, and at Spire Leicester Hospital. Notably, Dr Shah serves as the head of oncology for both the Leicester and Rutland Integrated Care System as well as Leicester General Hospital, a role he has held since 2012. Dr Shah is also the clinical quality and audit lead for the radiology department at University Hospitals of Leicester NHS Trust.

With over 17 years of clinical experience, Dr Shah originally qualified from the University of Leicester in 2007, achieving both an MBChB and an intercalated BSc degree. He completed his formal radiology training in 2015, before going on to accomplish two prestigious fellowships: a fellowship at Nuffield Orthopaedic Centre and a fellowship in radiation oncology at the Royal Orthopaedic Hospital. Additionally, Dr Shah holds the esteemed FRCR from the Royal College of Radiologists.

Dr Shah is a respected figure in his field, having given lectures and presentations on a national and international level. His contributions to the field also include the publication of peer-reviewed articles, as well as the authorship of book chapters on soft tissue tumour imaging. Furthermore, Dr Shah is an active member of various professional organisations, including the European Society of Medical Oncologists, the British Society of Skeletal Radiologists, and the American Society of Clinical Oncology.